(ABM FN) UCB has received positive reviews from the CHMP for bimekizumab in the European Union. announced this morning. These recommendations are supported by data from four Phase 3 studies, which tested bemicizumab in patients with active psoriatic arthritis and active axial spondyloarthritis.
If approved by the European Commission, this would be the second and third indications for pemicizumab in the European Union. The first approval for the treatment of moderate to severe plaque psoriasis in adults eligible for systemic therapy was granted in August 2021.
The European Commission’s decision is now expected within two months.
CHMP’s positive opinions are an important step towards UCB’s goal of providing patients with differentiated treatment options.
On the Brussels Stock Exchange, UCB closed at €85.26 on Wednesday.
Source: ABM Financial News
Following editors from Beursplein 5 ABC Financial News Developments on stock exchanges, and the Amsterdam Stock Exchange in particular, closely watched. The information in this column is not intended as professional investment advice or as a recommendation to make certain investments.
“Total coffee specialist. Hardcore reader. Incurable music scholar. Web guru. Freelance troublemaker. Problem solver. Travel trailblazer.”
More Stories
Bitcoin fell below $60,000 after the Israeli counterattack, but is recovering
Samsung switches to a six-day work week
Are there enough charging stations and can the electricity grid handle them? The five most frequently asked questions about electric driving